RBM12

Across TCGA pan-cancer cohorts, RBM12 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RBM12 data layer compared with 28 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RBM12 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RBM12 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

HNSC, CCRCC, and LSCC are the cancer types where RBM12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	All	0.781	0.991	.001	20	view →
CCRCC	OS	Tertile	All	0.876	1.000	.010	16	view →
LSCC	DFS	Quartile	All	0.904	0.624	.027	8	view →
GBM	OS	Tertile	All	0.510	0.281	.029	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RBM12–HNSC (OS)

Open the HNSC breakdown →